Ornella Cantale

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

Alessio Cortellini, Marcello Tiseo, Giuseppe Luigi Banna et al. · Cancer Immunology Immunotherapy · 2020 · 87 citations · Full text

Advanced Nsclc, Oncology, First-line Pembrolizumab Effectiveness +6

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Alessio Cortellini, Alex Friedlaender, Giuseppe Luigi Banna et al. · Clinical Lung Cancer · 2020 · 82 citations · Full text

Pd-l1 Expression, Clinical Epidemiology, Immunology +8

Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab

Giuseppe Luigi Banna, Diego Signorelli, Giulio Metro et al. · Translational Lung Cancer Research · 2020 · 64 citations · Full text

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm

Giuseppe Luigi Banna, Ornella Cantale, Melissa Bersanelli et al. · Oncology Reviews · 2020 · 49 citations · Full text

Anti-pd-l1 Agents, Anti-pd-l1 Alike, Medicine +12

Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non–Small Cell Lung Cancer With a PD-L1 Expression ≥50%

Giulio Metro, Giuseppe Luigi Banna, Diego Signorelli et al. · Journal of Immunotherapy · 2020 · 28 citations